<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: When presenting with <z:hpo ids='HP_0001953'>diabetic ketoacidosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e>), lean and <z:mp ids='MP_0001261'>obese</z:mp> patients differ in their subsequent clinical course </plain></SENT>
<SENT sid="1" pm="."><plain>Although lean patients tend to remain insulin dependent, most <z:mp ids='MP_0001261'>obese</z:mp> patients recover endogenous insulin secretion and discontinue insulin therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to determine whether <z:mp ids='MP_0001261'>obese</z:mp> African-American patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> could be determined to have type 1 or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> based on insulin secretion or the presence of immunological and genetic markers </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: This was a prospective study that analyzed the clinical characteristics, insulin secretion indices, immunological markers (islet cell, GAD, ICA512, and insulin autoantibodies), and HLA susceptibility genes (DR/DQ) in 131 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> (77 <z:mp ids='MP_0001261'>obese</z:mp> and 54 lean), 51 <z:mp ids='MP_0001261'>obese</z:mp> patients with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> but no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e>, and 25 nondiabetic subjects </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects were African-American </plain></SENT>
<SENT sid="5" pm="."><plain>Beta-cell function was evaluated by the C-<z:chebi fb="7" ids="16670">peptide</z:chebi> response to glucagon (1 mg i.v.) within 48 h of resolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> or <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The <z:hpo ids='HP_0011009'>acute</z:hpo> C-<z:chebi fb="7" ids="16670">peptide</z:chebi> response was lower in <z:mp ids='MP_0001261'>obese</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> patients (1.0+/-0.1 ng/ml) than in <z:mp ids='MP_0001261'>obese</z:mp> patients with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (1.7+/-0.2 ng/ml, P &lt; 0.01), but was higher than that in lean <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> patients (0.2+/-0.1 ng/ml, both P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>The overall prevalence of autoantibodies in <z:mp ids='MP_0001261'>obese</z:mp> subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> (17%) and <z:mp ids='MP_0001261'>obese</z:mp> subjects with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (16%) was lower than that in lean subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> (65%, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> patients with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and positive autoantibodies had lower rates of insulin secretion than those without antibodies </plain></SENT>
<SENT sid="9" pm="."><plain>Regardless of body weight, <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> patients with GAD autoantibodies carried the DQB1*0201 allele </plain></SENT>
<SENT sid="10" pm="."><plain>However, there were no significant differences in HLA distribution between the three patient groups </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results indicate that most <z:mp ids='MP_0001261'>obese</z:mp> African-American patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> have type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> characterized by higher insulin secretion, the absence of autoimmune markers, and a lack of HLA genetic association </plain></SENT>
<SENT sid="12" pm="."><plain>In contrast, most lean African-American patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e> have metabolic and immunological features of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>At presentation, assessment of beta-cell function and determination of autoimmune markers allow for correct classification of <z:mp ids='MP_0002055'>diabetes</z:mp> in African-Americans with hyperglycemic crises </plain></SENT>
</text></document>